SG11201603118TA - A telomerase encoding dna vaccine - Google Patents

A telomerase encoding dna vaccine

Info

Publication number
SG11201603118TA
SG11201603118TA SG11201603118TA SG11201603118TA SG11201603118TA SG 11201603118T A SG11201603118T A SG 11201603118TA SG 11201603118T A SG11201603118T A SG 11201603118TA SG 11201603118T A SG11201603118T A SG 11201603118TA SG 11201603118T A SG11201603118T A SG 11201603118TA
Authority
SG
Singapore
Prior art keywords
encoding dna
dna vaccine
telomerase
telomerase encoding
vaccine
Prior art date
Application number
SG11201603118TA
Other languages
English (en)
Inventor
Demoyen Pierre Langlade
Simon Wain-Hobson
Thierry Huet
Christelle Liard
Elodie Pliquet
Original Assignee
Invectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys filed Critical Invectys
Publication of SG11201603118TA publication Critical patent/SG11201603118TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201603118TA 2013-10-28 2014-10-28 A telomerase encoding dna vaccine SG11201603118TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13190547 2013-10-28
PCT/EP2014/073164 WO2015063117A1 (en) 2013-10-28 2014-10-28 A telomerase encoding dna vaccine

Publications (1)

Publication Number Publication Date
SG11201603118TA true SG11201603118TA (en) 2016-05-30

Family

ID=49515221

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603118TA SG11201603118TA (en) 2013-10-28 2014-10-28 A telomerase encoding dna vaccine

Country Status (26)

Country Link
US (2) US10183065B2 (hr)
EP (2) EP3062824B1 (hr)
JP (1) JP6545162B2 (hr)
KR (1) KR102252756B1 (hr)
CN (1) CN106061509B (hr)
AU (1) AU2014343813B2 (hr)
BR (1) BR112016009002B1 (hr)
CA (1) CA2927702C (hr)
CY (1) CY1122839T1 (hr)
DK (1) DK3062824T3 (hr)
EA (1) EA034928B1 (hr)
ES (1) ES2771862T3 (hr)
HK (1) HK1225986A1 (hr)
HR (1) HRP20200211T1 (hr)
HU (1) HUE047898T2 (hr)
IL (1) IL245186B (hr)
LT (1) LT3062824T (hr)
MX (1) MX2016005389A (hr)
NZ (1) NZ719098A (hr)
PL (1) PL3062824T3 (hr)
PT (1) PT3062824T (hr)
RS (1) RS60232B1 (hr)
SG (1) SG11201603118TA (hr)
SI (1) SI3062824T1 (hr)
WO (1) WO2015063117A1 (hr)
ZA (1) ZA201603452B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3062824T1 (sl) 2013-10-28 2020-04-30 Invectys Cepivo telomeraza kodirajoče DNA
AU2016335070B2 (en) * 2015-10-06 2022-03-17 Invectys Polyepitope constructs for use in immunotherapy
US11351246B2 (en) 2017-05-09 2022-06-07 Invectys SAS Recombinant measles vaccine expressing hTERT
JP2022541070A (ja) * 2019-07-25 2022-09-21 ノバルティス アーゲー 調節可能な発現系
CN115605596A (zh) * 2020-02-12 2023-01-13 费城儿童医院（Us） 用于基因表达的诱导型可变剪接调节的组合物和方法
WO2021263081A2 (en) * 2020-06-26 2021-12-30 National Breast Cancer Coalition Breast cancer vaccine
CN116870195A (zh) * 2020-09-22 2023-10-13 浙江愈方生物科技有限公司 一种灭活性端粒酶、具有其的腺病毒和人造mRNA及应用
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use
WO2024126758A2 (en) * 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504416A (ja) 1989-02-17 1992-08-06 コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． ペプチドの使用方法と合成方法
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
SG94355A1 (en) 1996-10-01 2003-02-18 Geron Corp Human telomerase catalytic subunit
WO2003038047A2 (en) 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
CA2490863A1 (en) 2002-06-27 2004-01-08 Geron Corporation Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US20090162405A1 (en) 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
RU2473691C2 (ru) 2006-10-12 2013-01-27 Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа Слитый белок теломеразной обратной транскриптазы, кодирующие его нуклеотиды и их применение
EP2282776A4 (en) * 2008-04-11 2011-11-09 Lsip Llc INDUCER OF APOPTOSIS
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
JP2012039877A (ja) 2009-04-10 2012-03-01 Fukuoka Univ ユビキチン融合遺伝子およびそれを用いたｄｎａワクチン
WO2011073796A2 (en) 2009-12-16 2011-06-23 Chrontech Pharma Ab Injection needle and device
DK2978444T3 (en) 2013-03-28 2019-03-18 Invectys CANCERVACCINE FOR DOGS
DK2978445T3 (en) 2013-03-28 2018-10-15 Invectys A CANCERVACCINE FOR CAT
SI3062824T1 (sl) 2013-10-28 2020-04-30 Invectys Cepivo telomeraza kodirajoče DNA
US20160347798A1 (en) * 2014-01-27 2016-12-01 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides and cell-targeted molecules for direct cell killing and immune stimulation via mhc class i presentation and methods regarding the same

Also Published As

Publication number Publication date
US10183065B2 (en) 2019-01-22
EA201690884A1 (ru) 2016-11-30
IL245186B (en) 2021-02-28
EA034928B1 (ru) 2020-04-08
ES2771862T3 (es) 2020-07-07
LT3062824T (lt) 2020-05-25
EP3062824B1 (en) 2019-11-27
HUE047898T2 (hu) 2020-05-28
NZ719098A (en) 2022-08-26
WO2015063117A1 (en) 2015-05-07
EP3666290A1 (en) 2020-06-17
RS60232B1 (sr) 2020-06-30
MX2016005389A (es) 2016-08-03
HRP20200211T1 (hr) 2020-05-15
BR112016009002A2 (pt) 2017-10-03
SI3062824T1 (sl) 2020-04-30
US20160263204A1 (en) 2016-09-15
CN106061509A (zh) 2016-10-26
US12064474B2 (en) 2024-08-20
AU2014343813B2 (en) 2020-02-27
CN106061509B (zh) 2022-04-08
CA2927702C (en) 2022-06-07
EP3062824A1 (en) 2016-09-07
ZA201603452B (en) 2020-08-26
PT3062824T (pt) 2020-02-21
CY1122839T1 (el) 2021-10-29
AU2014343813A1 (en) 2016-05-19
CA2927702A1 (en) 2015-05-07
JP6545162B2 (ja) 2019-07-17
JP2017502649A (ja) 2017-01-26
BR112016009002B1 (pt) 2023-05-02
US20190000946A1 (en) 2019-01-03
KR102252756B1 (ko) 2021-05-17
KR20160111362A (ko) 2016-09-26
IL245186A0 (en) 2016-06-30
PL3062824T3 (pl) 2020-06-15
HK1225986A1 (zh) 2017-09-22
DK3062824T3 (da) 2020-02-17

Similar Documents

Publication Publication Date Title
IL276210A (en) MERS-COV vaccine
HRP20181376T1 (hr) Poboljšana cjepiva protiv poksvirusa
HRP20200211T1 (hr) Telomeraza kodiranja dnk cjepiva
HK1226440A1 (zh) Cmv疫苗
ZA201508642B (en) Malaria vaccine
HK1218872A1 (zh) 乙型肝炎疫苗
GB201318084D0 (en) Malaria vaccination
GB201301085D0 (en) Glycoconjugate Vaccine
HK1217206A1 (zh) 疫苗
GB201301119D0 (en) Viral vaccines
GB201315714D0 (en) DNA Construct
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
GB201303749D0 (en) STA Eagle